Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.79 (
hormone-sensitive lipase
)
2,163
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Prostaglandin (PG) D
2
enhanced lipid accumulation in adipocytes. However, its molecular mechanism remains unclear. In this study, we investigated the regulatory mechanisms of PGD
2
-elevated lipid accumulation in mouse adipocytic 3T3-L1 cells. The Gi-coupled DP2 (
CRTH2
) receptors (DP2R), one of the two-types of PGD
2
receptors were dominantly expressed in adipocytes. A DP2R antagonist, CAY10595, but not DP1 receptor antagonist, BWA868C cleared the PGD
2
-elevated intracellular triglyceride level. While, a DP2R agonist, 15R-15-methyl PGD
2
(15R) increased the mRNA levels of the adipogenic and lipogenic genes, and decreased the glycerol release level. In addition, the forskolin-mediated increase of cAMP-dependent protein kinase A (PKA) activity and phosphorylation of
hormone-sensitive lipase
(
HSL
) was repressed by the co-treatment with 15R. Moreover, the lipolysis was enhanced in the adipocyte-differentiated DP2R gene-knockout mouse embryonic fibroblasts. These results indicate that PGD
2
suppressed the lipolysis by repression of the cAMP-PKA-
HSL
axis through DP2R in adipocytes.
...
PMID:Prostaglandin D
2
enhances lipid accumulation through suppression of lipolysis via DP2 (CRTH2) receptors in adipocytes. 2862 33
